Longevity Medical Institute launches intranasal regenerative neurology platform

Longevity Medical Institute in San José del Cabo has launched a new regenerative neurology program that uses an intranasal delivery system to send therapies toward the brain without a lumbar puncture. The institute says the option expands treatment planning for selected neurological conditions alongside intrathecal care.

Why it matters: - Longevity Medical Institute’s new platform gives physicians another delivery option for selected neurological conditions, with the goal of reducing invasiveness compared with intrathecal administration. - The launch adds a non-invasive nose-to-brain approach to a treatment area where getting therapies past the blood-brain barrier remains a major challenge. - The institute is positioning the platform as part of broader personalized care for patients with neurological disorders.

What happened: - Longevity Medical Institute launched its Regenerative Neurological Therapy Program on July 23, 2026, in San José del Cabo, Baja California Sur, Mexico. - The program includes an advanced intranasal delivery platform designed to transport regenerative therapies through the nasal cavity toward the brain. - The institute says the platform offers a non-invasive alternative to intrathecal administration for clinically appropriate cases. - Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute, said the addition expands the institute’s ability to personalize treatment and lets physicians choose between intrathecal and intranasal administration based on diagnosis, clinical findings and treatment goals.

The details: - The intranasal system is built to target the upper nasal cavity near the olfactory region, rather than the lower nasal passages reached by conventional sprays. - Research cited in the announcement indicates compounds delivered to the olfactory region may travel toward the brain through the olfactory and trigeminal nerve pathways. - The platform uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer generates microscopic aerosol droplets and delivers them gradually over several minutes. - The controlled delivery is intended to increase contact time in the olfactory region, reduce medication loss into the throat and improve delivery consistency. - Longevity Medical Institute uses the platform exclusively for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes and selected therapeutic peptides. - Treatment recommendations come from the institute’s multidisciplinary physician team after a neurological evaluation that may include advanced imaging, laboratory testing, a neurological exam and review of medical history. - The institute’s broader neurological program also includes intravenous regenerative therapies, intrathecal administration in a fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging and multidisciplinary physician care.

Between the lines: - The launch reflects growing interest in non-invasive delivery routes for therapies aimed at the central nervous system. - The announcement leans on published human research suggesting MSC-based therapies have a favorable safety profile across several neurological conditions, including ischemic stroke, multiple sclerosis, ALS, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury and cerebral palsy. - The institute says larger randomized clinical trials are still needed to determine which patients benefit most and how durable responses may be. - The positioning suggests the platform is meant to broaden clinical flexibility rather than replace intrathecal treatment entirely.

What’s next: - Longevity Medical Institute will continue offering treatment recommendations based on physician evaluation, published evidence, patient-specific factors and clinical judgment. - The institute says regenerative neurological therapies remain a fast-growing area of translational medicine. - More information is available in the institute’s announcement.

The bottom line: - Longevity Medical Institute is betting that intranasal delivery can make regenerative neurology less invasive while preserving physician choice for complex brain and nervous system treatments.